Search research articles
Contact Us
Filters
Showing results (11-20 of 56) with videos related to
Page
of 6
Sort By:
Current Pharmaceutical Design
|
February 15, 2001
Immunology of VIP: a review and therapeutical perspectives
R P Gomariz, C Martinez, C Abad, et al.
European Journal of Immunology
|
November 28, 2000
Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock
M Delgado, R P Gomariz, C Martinez, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 7, 2001
Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy
C Abad, C Martinez, J Leceta, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 11, 1999
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies
M Delgado, E J Munoz-Elias, R P Gomariz, et al.
Journal of Neuroimmunology
|
May 25, 1999
VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells
M Delgado, E J Munoz-Elias, R P Gomariz, et al.
Peptides
|
January 1, 1996
Pituitary adenylate cyclase-activating polypeptide (PACAP-38) stimulates rat peritoneal macrophage functions
M Delgado, E Garrido, M de la Fuente, et al.
Nature Medicine
|
May 1, 2001
Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease
M Delgado, C Abad, C Martinez, et al.
Journal of Neuroimmunology
|
November 1, 1995
Pituitary adenylate cyclase-activating polypeptides (PACAP27 and PACAP38) inhibit the mobility of murine thymocytes and splenic lymphocytes: comparison with VIP and implication of cAMP
M Delgado, M De la Fuente, C Martínez, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 14, 1999
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation
M Delgado, E J Munoz-Elias, R P Gomariz, et al.
Annals of the New York Academy of Sciences
|
February 24, 2001
VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression
M Delgado, J Leceta, W Sun, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 56) with videos related to
Sort By:
Page
of 6
Current Pharmaceutical Design
|
February 15, 2001
Immunology of VIP: a review and therapeutical perspectives
R P Gomariz, C Martinez, C Abad, et al.
European Journal of Immunology
|
November 28, 2000
Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock
M Delgado, R P Gomariz, C Martinez, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 7, 2001
Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy
C Abad, C Martinez, J Leceta, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 11, 1999
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies
M Delgado, E J Munoz-Elias, R P Gomariz, et al.
Journal of Neuroimmunology
|
May 25, 1999
VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells
M Delgado, E J Munoz-Elias, R P Gomariz, et al.
Peptides
|
January 1, 1996
Pituitary adenylate cyclase-activating polypeptide (PACAP-38) stimulates rat peritoneal macrophage functions
M Delgado, E Garrido, M de la Fuente, et al.
Nature Medicine
|
May 1, 2001
Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease
M Delgado, C Abad, C Martinez, et al.
Journal of Neuroimmunology
|
November 1, 1995
Pituitary adenylate cyclase-activating polypeptides (PACAP27 and PACAP38) inhibit the mobility of murine thymocytes and splenic lymphocytes: comparison with VIP and implication of cAMP
M Delgado, M De la Fuente, C Martínez, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 14, 1999
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation
M Delgado, E J Munoz-Elias, R P Gomariz, et al.
Annals of the New York Academy of Sciences
|
February 24, 2001
VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression
M Delgado, J Leceta, W Sun, et al.
Page
of 6